Approved for use through 07/31/2012. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10568654		
Filing Date		2007-02-22		
First Named Inventor Micha		ael Patrick Murphy		
Art Unit		1614		
Examiner Name Rayn		nond J. Henley III		
Attorney Docket Number		110199.405USPC		

Examiner					PATENTS	
	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	6331532	В1	2001-12-18	Murphy et al.	
	2	6673908	B1	2004-01-06	Stanton Jr., Vincent P.	
	3	6825179	B2	2004-11-30	Nielsen et al.	
	4	6861447	B2	2005-03-01	Moldenhauer et al.	
	5	7109189	B2	2006-09-19	Murphy et al.	
	6	7179928	B2	2007-02-20	Smith et al.	
	7	7232809	B2	2007-06-19	Murphy et al.	
f you wish	n to ad	d additional U.S. Pat	tent citatio	n information	please click the Add button.	

Application Number 10568654 Filing Date 2007-02-22

INFORMATION DISCLOSURE	First Named Inventor	Micha	ael Patrick Murphy	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1,99)	Art Unit		1614	
Not for outsinicolon under or or it 1.00,	Examiner Name	Raym	nond J. Henley III	
	Attorney Docket Numb	er	110199.405USPC	

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20090258841	A1	2009-10-15	Murphy et al.	
If you wish	h to add a	dditional II S Dub	lichad Ar	nlication citatio	n information please click the Ad	d hutton

FOREIGN PATENT DOCUMENTS

Examiner Cite Foreign Document Country Code ² i Code ² i Publication P			10.0	LIGHTA	Litt DOGG.	LITTO		
1 0535283 EP A1 1993-11-22 Pharmaceutical Inc. 2 03074395 JP A 1991-03-28 Nippon Chem Ind Co Ltd 3 2002104922 JP A 2002-04-10 Beiersdorf AG+ 4 2003520827 JP A 2003-07-08 Wacker-Chemie GmbH 5 2005019233 WO A1 2005-03-03 Antipodean Biotechnology Limited						Applicant of cited	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Т5
3 2002104922 JP A 2002-04-10 Beiersdorf AG+ 4 2003-07-08 Wacker-Chemie GmbH 5 2005019233 WO A1 2005-03-03 Antipodean Biotechnology Limited	1	0535283	EP	A1	1993-11-22			
4 2003520827 JP A 2003-07-08 Wacker-Chemie GmbH 5 2005019233 WO A1 2005-03-03 Antipodean Biotechnology Limited	2	03074395	JP	A	1991-03-28	Nippon Chem Ind Co Ltd		
5 2005019233 WO A1 2005-03-03 Antipodean Biotechnology Limited	3	2002104922	JP	A	2002-04-10	Beiersdorf AG+		
5 2009/19233 WO A1 2009-03-03 Biotechnology Limited	4	2003520827	JP	A	2003-07-08	Wacker-Chemie GmbH		
	5	2005019233	wo	A1	2005-03-03			
Pharmaceuticals, Inc.	6	2009145982	wo	A1	2009-12-03	Antipodean Pharmaceuticals, Inc.		

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10568654		
Filing Date		2007-02-22		
First Named Inventor	Mich	nael Patrick Murphy		
Art Unit		1614		
Examiner Name	Ray	mond J. Henley III		
Attorney Docket Number		110199.405USPC		

PITAL LETTERS), title of the article (when appropriate), title of the item symposium, catalog, etc), date, pages(s), volume-issue number(s), re published.	T5
hydrophobicity of a mitochondria-targeted antioxidant," FEBS Letters 571:9-16,	
organophosphorus compounds," Pakistan J. of Scientific and Industrial Research e 1, 1986.	
Redox-active Ubiquinone to Mitochondria within Cells," Journal of Biological 2001.	
nt ubiquinones on the scavenging of biologically generated superoxide," Drugs earch 11(8):529-532, Abstract Only, from CAPLUS, Accession Number	
ing of bioactive compounds to mitochondria," Trends in Biotechnology 15	
e pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline- 399-406, 2002.	
lomere shortening and elongates lifespan of fibroblasts under mild oxidative	
olecules to mitochondria in vivo," PNAS 100(9):5407-5412, April 29, 2003.	
d parameters in the liver of non-alcoholic fatty liver disease patients," Clinical	
	d parameters in the liver of non-alcoholic fatty liver disease patients," Clinical

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10568654			
Filing Date	2007-02-22				
First Named Inventor	Mich	Michael Patrick Murphy			
Art Unit		1614			
Examiner Name	Raymond J. Henley III				
Attorney Docket Numb	er	110199.405USPC			

	EXAMINER SIGNATURE
Examiner Signature	Date Considered
	r or not citation is in conformance with MPEP 609. Draw line through a notude copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if Enolish Inaquase translation is attached.